相关实验视频
Updated: Jan 12, 2026

09:52
An Implantable System For Chronic In Vivo Electromyography
Published on: April 21, 2020
11.2K
麻醉治疗先天性帕拉米托尼:一个叙事审查
Marianne Chee1, Suhitharan Thangavelautham2, Jing Hui Chen2
1Anaesthesiology and Critical Care, Singapore General Hospital, Singapore, SGP.
Cureus
|October 30, 2025
概括
帕拉米托尼亚先天性 (PMC) 是一种罕见的神经肌肉疾病,导致肌肉硬. 本综述指导麻醉科医生对PMC患者的安全麻醉管理,强调避免触发和控制温度.
科学领域:
- 麻醉学 麻醉学
- 神经肌肉疾病 神经肌肉疾病
- 医学遗传学 医学遗传学
背景情况:
- 帕拉米托尼亚先天性 (PMC) 是一种罕见的,非进展性神经肌肉疾病.
- 肌肉硬和收缩或刺激后延迟放松的特征.
- 由于罕见的临床接触,稀有性带来了麻醉管理的挑战.
研究的目的:
- 综合有关Paramyotonia Congenita患者麻醉管理的文献.
- 为麻醉医生提供PMC外科手术期考虑的专注理解.
- 为了突出选择麻醉剂和报告的安全实践的结果.
主要方法:
- 现有文献的叙述性审查.
- 对PMC患者麻醉管理的综合研究.
- 确定经常出现的管理原则和报告的结果.
主要成果:
- 对于PMC患者的麻醉技术有所不同.
- 关键的管理原则包括避免硬触发因素,并保持谨慎的温度控制.
- 准备好管理潜在的并发症至关重要.
结论:
- 虽然对于PMC没有单一的最佳麻醉方法.
- 目前的文献表明,安全麻醉是可以通过计划和警来实现的.
- 术后护理需要特别注意PMC的独特特征.
更多相关视频
相关概念视频
Skeletal Muscle Relaxants: Therapeutic Uses
878
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
878
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Myasthenia Gravis: Diagnostic Tests
1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
881
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
881
Skeletal Muscle Relaxants: Adverse Effects
767
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
767
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
2.7K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.7K

